ARTICLE | Company News
Virogen, Aventis deal
March 5, 2001 8:00 AM UTC
Virogen completed its previously announced license of AVE’s VIR-101, a nucleoside analog to treat hepatitis B virus (HBV) infection and HIV infection, and VIR-222, a broad-spectrum antiviral glycoprot...